NO20070930L - Stabiliserende formuleringer - Google Patents

Stabiliserende formuleringer

Info

Publication number
NO20070930L
NO20070930L NO20070930A NO20070930A NO20070930L NO 20070930 L NO20070930 L NO 20070930L NO 20070930 A NO20070930 A NO 20070930A NO 20070930 A NO20070930 A NO 20070930A NO 20070930 L NO20070930 L NO 20070930L
Authority
NO
Norway
Prior art keywords
protein
storing
methods
relatively low
stabilizing formulations
Prior art date
Application number
NO20070930A
Other languages
English (en)
Norwegian (no)
Inventor
Li Li
Angela Kantor
Shannon B Macmillan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20070930L publication Critical patent/NO20070930L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20070930A 2004-08-13 2007-02-19 Stabiliserende formuleringer NO20070930L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60131104P 2004-08-13 2004-08-13
PCT/US2005/028861 WO2006020935A2 (en) 2004-08-13 2005-08-12 Stabilizing formulations

Publications (1)

Publication Number Publication Date
NO20070930L true NO20070930L (no) 2007-05-14

Family

ID=35908214

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070930A NO20070930L (no) 2004-08-13 2007-02-19 Stabiliserende formuleringer

Country Status (18)

Country Link
US (1) US8871201B2 (ko)
EP (1) EP1784219B1 (ko)
JP (1) JP4948407B2 (ko)
KR (1) KR20070092197A (ko)
CN (1) CN101022831A (ko)
AR (1) AR051009A1 (ko)
AU (1) AU2005272603A1 (ko)
BR (1) BRPI0514340A (ko)
CA (1) CA2575870A1 (ko)
CR (1) CR8904A (ko)
EC (1) ECSP077246A (ko)
ES (1) ES2637854T3 (ko)
IL (1) IL181265A0 (ko)
MX (1) MX2007001599A (ko)
NO (1) NO20070930L (ko)
RU (1) RU2007109062A (ko)
TW (1) TW200621282A (ko)
WO (1) WO2006020935A2 (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
AU2007240732B2 (en) * 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
WO2007124299A2 (en) * 2006-04-21 2007-11-01 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
US20080070230A1 (en) * 2006-06-12 2008-03-20 Wyeth Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions
EP1950225A1 (de) * 2007-01-25 2008-07-30 Octapharma AG Verfahren zur Steigerung von Proteinausbeuten
WO2008121301A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human il-12 antibodies
NZ602498A (en) * 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20100172862A1 (en) * 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
CA2760185A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha antibodies
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
CN103930124B (zh) 2011-07-01 2021-05-11 生物基因Ma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法
KR102143435B1 (ko) 2011-11-30 2020-08-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 펩티드 치료제 및 아미노산을 포함하는 마이크로니들 장치 및 이의 제조 및 사용 방법
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
JP6265970B2 (ja) * 2012-03-26 2018-01-24 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2014099636A1 (en) * 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
US9381205B2 (en) 2013-11-04 2016-07-05 Pfizer, Inc. Anti-EFNA4 antibody-drug conjugates
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3194977B1 (en) * 2014-07-21 2019-10-02 Unchained Labs Determination of protein aggregation from the concentration dependence of delta g
MX2017013802A (es) 2015-04-29 2018-08-15 Radius Pharmaceuticals Inc Métodos para tratar el cáncer.
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EP3761035B1 (en) * 2016-08-18 2024-02-14 Regeneron Pharmaceuticals, Inc. Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.
MX2019007748A (es) 2017-01-05 2019-09-09 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
KR20230131212A (ko) * 2021-01-14 2023-09-12 한올바이오파마주식회사 안정화제를 사용하지 않고도 안정한, 탄파너셉트를포함하는 안과용 조성물
CN115541895B (zh) * 2022-11-29 2023-05-19 天津德祥生物技术股份有限公司 一种提高微流控反定检测卡灵敏度的配方液及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3176517D1 (en) * 1980-04-24 1987-12-17 Beecham Group Plc Beta-lactam compounds, their preparation and use
GB8518416D0 (en) 1985-07-22 1985-08-29 Beecham Group Plc Compounds
US5869053A (en) * 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2292760A1 (en) * 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Vector
EP0999853B1 (en) * 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
WO1999037329A1 (en) 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US20030124119A1 (en) * 1999-12-28 2003-07-03 Tadao Yamazaki Stable antibody compositions and injection preparations
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
WO2002030463A2 (en) * 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP2005532258A (ja) * 2002-01-03 2005-10-27 スミスクライン・ビーチャム・コーポレイション 免疫コンジュゲートの調製方法
EP1507556B1 (en) * 2002-05-02 2016-07-27 Wyeth Holdings LLC Calicheamicin derivative-carrier conjugates
WO2004001007A2 (en) 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20080268459A1 (en) 2003-08-14 2008-10-30 Wyeth Ludwig Institute For Cancer Anti-Lewis Y Anti-Idiotypic Antibodies and Uses Thereof
US20060088522A1 (en) * 2004-09-10 2006-04-27 Wyeth Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugates

Also Published As

Publication number Publication date
CN101022831A (zh) 2007-08-22
AU2005272603A1 (en) 2006-02-23
EP1784219A2 (en) 2007-05-16
AR051009A1 (es) 2006-12-13
MX2007001599A (es) 2007-04-10
US20060115472A1 (en) 2006-06-01
WO2006020935A2 (en) 2006-02-23
ECSP077246A (es) 2007-05-30
EP1784219A4 (en) 2010-02-17
KR20070092197A (ko) 2007-09-12
JP4948407B2 (ja) 2012-06-06
ES2637854T3 (es) 2017-10-17
JP2008515775A (ja) 2008-05-15
BRPI0514340A (pt) 2008-06-10
CA2575870A1 (en) 2006-02-23
US8871201B2 (en) 2014-10-28
EP1784219B1 (en) 2017-05-17
TW200621282A (en) 2006-07-01
IL181265A0 (en) 2007-07-04
RU2007109062A (ru) 2008-09-20
WO2006020935A3 (en) 2007-03-08
CR8904A (es) 2007-08-28

Similar Documents

Publication Publication Date Title
NO20070930L (no) Stabiliserende formuleringer
JP2008515775A5 (ko)
Nynca et al. Standardization of spermatozoa concentration for cryopreservation of rainbow trout semen using a glucose-methanol extender
AR047949A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial
CN104255713B (zh) 月季切花保鲜剂及其保鲜应用
NO20085131L (no) Lyofiliserte preparater av anti-EGFR-antistoffer
WO2007037795A3 (en) Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CH688194A5 (fr) Composition stabilisée de troponine pour immunoessais et procédé de stabilisation de troponine pour immunoessais.
PL407889A1 (pl) Przeciwciało przeciwko receptorowi insulinopodobnego czynnika wzrostu I, zawierająca go kompozycja farmaceutyczna, sposób jego wytwarzania, zastosowania, linia komórkowa, wyizolowana cząsteczka kwasu nukleinowego, wektor, komórka gospodarza oraz zwierzę trangeniczne
EP1371643A3 (en) Method of preparing organic peroxyacids
Clifford et al. Crustacean zooplankton release copious amounts of dissolved organic matter as taurine in the ocean
BR0314455A (pt) Derivados de aminoálcool, seus sais e agentes imunosupressores
Temel et al. Purification of glutathione S‐transferase enzyme from quail liver tissue and inhibition effects of (3aR, 4S, 7R, 7aS)‐2‐(4‐((E)‐3‐(aryl) acryloyl) phenyl)‐3a, 4, 7, 7a‐tetrahydro‐1H‐4, 7‐methanoisoindole‐1, 3 (2H)‐dione derivatives on the enzyme activity
Hou et al. Analysis of glutathione in biological samples by HPLC involving pre-column derivatization with o-phthalaldehyde
JP2014501526A5 (ko)
Chang et al. Cl− uptake mechanism in freshwater-adapted tilapia (Oreochromis mossambicus)
Elzaki et al. Activiation of the nitric oxide cycle by citrulline and arginine restores susceptibility of resistant brown planthoppers to the insecticide imidacloprid
Cleal et al. Modification of fetal plasma amino acid composition by placental amino acid exchangers in vitro
DE602004013021D1 (de) Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung
EA200501789A1 (ru) Стабильный водный раствор эритропоэтина человека, не содержащий сывороточного альбумина
NO20073549L (no) Fremgangsmate for fremstilling av organiske forbindelser
JP2009002709A (ja) 蛋白質を含む液状組成物中における蛋白質の安定化方法
Judycka et al. Cryopreserved rainbow trout semen can be used for the fertilization of up to 8000 eggs in a single application
EP1801232A4 (en) METHOD FOR SORTING TRANSMEMBRANE ENZYME INHIBITOR SUBSTANCE
DK1833308T3 (da) Ögning af proteinandelen af dyriske organismer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application